New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2013
19:14 EDTAMGNInterim results from Amgen Phase 2 study published
Amgen announced the Lancet Oncology published planned interim results from an international, open-label, Phase 2 clinical trial that is evaluating Xgeva in adults and skeletally mature adolescents diagnosed with giant cell tumor of bone. The study's primary endpoint is the safety profile of Xgeva. Secondary endpoints are the time to disease progression and the proportion of patients without any surgery at six months. Based on the investigators' interim assessment, 96% of patients with surgically unsalvageable GCTB had no disease progression after a median follow-up of 13 months. In those with salvageable GCTB whose surgery was associated with severe morbidity, 74% of patients required no surgery, and 62% of patients who had surgery underwent a less morbid procedure than planned. Overall, 72% of patients had objective tumor response, per protocol defined criteria, including 25% of patients who had an objective tumor response according to modified response evaluation criteria in solid tumors. The overall safety profile was found to be consistent with the known safety profile of Xgeva in patients with advanced cancer. Osteonecrosis of the jaw was reported in 1% of patients. Hypocalcemia adverse events, all non-serious, were reported in 5% of patients. The most common severe adverse events were low phosphate levels, back pain, pain in extremity, depression, musculoskeletal pain and anemia. Serious adverse events were reported in 9% of patients. No treatment-related deaths were reported.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
19:05 EDTAMGNBayer, Onyx report publishing of positive Phase 3 trial results
Subscribe for More Information
13:56 EDTAMGNAmgen sell-off creates buying opportunity, says Argus
After Amgen reported weaker than expected Q1 results, Argus believes that the company's key growth drivers performed well last quarter. The firm thinks the company's growth outlook looks solid, and it keeps a Buy rating on the shares.
09:34 EDTAMGNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD NFLX TSLA VZ MU WFM AMGN
09:16 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAMGNAmgen weakness a buying opportunity, says Cowen
Cowen would use any weakness in Amgen as buying opportunity and said the recent shortfall was due to seasonal factors and that 2014 remains on track. The firm cited company guidance, its superior profile relative to peers, potential for increased dividends, and a maturing pipeline. Shares are Outperform rated with a $131 price target.
06:54 EDTAMGNCambridge Healthtech Institute to hold a conference
Subscribe for More Information
06:53 EDTAMGNFood & Drug Law Institute to hold a conference
Subscribe for More Information
April 22, 2014
16:32 EDTAMGNAmgen says total product sales declined 9% sequentially in Q1
Subscribe for More Information
16:25 EDTAMGNAmgen trades lower after results, first look
Subscribe for More Information
16:06 EDTAMGNAmgen sees FY14 EPS $7.90-$8.20, consensus $8.16
Subscribe for More Information
16:05 EDTAMGNAmgen reports Q1 EPS $1.87, consensus $1.94
Subscribe for More Information
15:32 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
14:35 EDTAMGNEarnings Preview: Amgen's timeline for Evolocumab will be in focus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use